Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab

被引：0
|
作者：
Fayez Estephan
Xiaobu Ye
Omar Dzaye
Nina Wagner-Johnston
Lode Swinnen
Douglas E. Gladstone
Rich Ambinder
David Olayinka Kamson
Sebastian Lambrecht
Stuart A. Grossman
Doris D. M. Lin
Matthias Holdhoff
机构：
[1] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Department of Neurosurgery
[2] Johns Hopkins University School of Medicine,Russell H. Morgan Department of Radiology and Radiological Science
[3] Johns Hopkins University School of Medicine,Department of Radiology and Neuroradiology
[4] Charité,Division of Neuroradiology, Russell H. Morgan Department of Radiology and Radiological Science
[5] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[6] Johns Hopkins University School of Medicine,undefined
来源：
Journal of Neuro-Oncology | 2019年 / 145卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The following discrepancies and errors were found in the original publication:
引用
收藏
页码：467 / 467
相关论文
共 50 条
  • [21] Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate
    Stewart, Colin
    Owen, Carolyn
    Street, Lesley
    Hay, Kevin
    Perry, Sarah
    Duggan, Peter
    Shafey, Mona
    Balogh, Alex
    Cao, Jeffrey
    Chua, Neil
    Stewart, Douglas
    Puckrin, Robert
    LEUKEMIA & LYMPHOMA, 2025,
  • [22] Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
    Yuan, Xianggui
    Yu, Teng
    Huang, Yurong
    Jiang, Huawei
    Xu, Xiaohua
    Liang, Yun
    Qian, Wenbin
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [23] Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
    Xianggui Yuan
    Teng Yu
    Yurong Huang
    Huawei Jiang
    Xiaohua Xu
    Yun Liang
    Wenbin Qian
    Scientific Reports, 12 (1)
  • [24] Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis
    Lai, Gillianne Geet Yi
    Koo, Yu Xuan
    Tao, Miriam
    Tan, Thuan Tong
    Lim, Soon-Thye
    ACTA ONCOLOGICA, 2011, 50 (01) : 144 - 145
  • [25] High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL)
    Salamoon, Maher
    Hussein, Taisir
    Kenj, Mazen
    Bachour, Marrouan
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [26] High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL)
    Maher Salamoon
    Taisir Hussein
    Mazen Kenj
    Marrouan Bachour
    Medical Oncology, 2013, 30
  • [27] A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
    Villanueva, Gabriela
    Guscott, Martin
    Schaiquevich, Paula
    Sampor, Claudia
    Combs, Ryan
    Tentoni, Nicolas
    Hwang, Miriam
    Lowe, Jennifer
    Howard, Scott
    CANCERS, 2023, 15 (05)
  • [28] Outcome after high-dose methotrexate and radiotherapy for primary central nervous system lymphoma
    Choi, J. H.
    Kim, I. H.
    Heo, D. S.
    Jung, H. W.
    EJC SUPPLEMENTS, 2009, 7 (02): : 501 - 501
  • [29] High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma
    Yadav, Budhi Singh
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (03):
  • [30] Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma
    Hanna, Colette
    Villa, Diego
    Irani, Carla
    Ghosn, Marwan
    El Rassy, Elie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05): : E197 - E200
12345